Classical and Emerging Roles of Vitamin D in Hepatitis C Virus Infection

ABSTRACT

According to the Institute of Medicine, the risk of clinically significant vitamin D deficiency increases at 25-hydroxyvitamin D levels below 20 ng/mL. By this standard, most cirrhotic hepatitis C virus- (HCV-) positive patients and many noncirrhotic patients are vitamin D-deficient. The high prevalence of vitamin D deficiency among HCV patients is a cause for concern for several specific reasons. Classic studies established the importance of vitamin D and calcium in maintaining bone. Vitamin D's beneficial effects on bone are likely to be vital for HCV-infected patients because these individuals have a high prevalence of low bone mineral density. Many pharmaceutical agents reduce bone density and exposure to these drugs may increase bone disease in HCV-positive patients. Bone loss occurs following liver transplantation and bone density is often low in patients with HIV/HCV co-infection who are on combination antiretroviral therapy. Some evidence suggests that ribavirin reduces bone density, underscoring the special need to monitor vitamin D in patients receiving HCV treatment and to prescribe supplements, as appropriate. In addition to its role in calcium metabolism, vitamin D is also an immune modulator that reduces inflammation while enhancing protective immune responses. Higher vitamin D levels are associated with less liver fibrosis and less inflammation in HCV patients. Recent studies show that low vitamin D levels are associated with treatment failure among HCV-infected patients receiving pegylated-interferon and ribavirin. If confirmed, these findings will provide an additional reason to ensure adequate levels of vitamin D. Information about how to monitor vitamin D status and how to use vitamin D supplements most effectively in HCV-infected patients is provided.

KEYWORDS

Hepatitis C virus - vitamin D - hepatocellular carcinoma - bone mineral density - fracture - fibrosis - sustained virologic response - interferon - ribavirin

REFERENCES

• 1 Ross A C, Taylor C L, Yaktine A L, Del Valle H B eds.. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Washington, DC: The National Academic Press; 2011
• 2 Holick M F, Binkley N C, Bischoff-Ferrari H A Endocrine Society et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.  J Clin Endocrinol Metab. 2011;  96 (7) 1911-1930
• 3 Tang B M, Eslick G D, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.  Lancet. 2007;  370 (9588) 657-666
• 4 Melhus H, Snellman G, Gedeborg R et al.. Plasma 25-hydroxyvitamin D levels and fracture risk in a community-based cohort of elderly men in Sweden.  J Clin Endocrinol Metab. 2010;  95 (6) 2637-2645
• 5 Ensrud K E, Taylor B C, Paudel M L Osteoporotic Fractures in Men Study Group et al. Serum 25-hydroxyvitamin D levels and rate of hip bone loss in older men.  J Clin Endocrinol Metab. 2009;  94 (8) 2773-2780
• 6 Bischoff-Ferrari H A, Dietrich T, Orav E J, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults.  Am J Med. 2004;  116 (9) 634-639
• 7 Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications.  Endocr Rev. 2001;  22 (4) 477-501
• 8 McKenna M J, Freaney R. Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D.  Osteoporos Int. 1998;  8 (Suppl 2) S3-S6
• 9 Krall E A, Sahyoun N, Tannenbaum S, Dallal G E, Dawson-Hughes B. Effect of vitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women.  N Engl J Med. 1989;  321 (26) 1777-1783
• 10 Thomas S D, Need A G, Tucker G, Slobodian P, O’Loughlin P D, Nordin B E. Suppression of parathyroid hormone and bone resorption by calcium carbonate and calcium citrate in postmenopausal women.  Calcif Tissue Int. 2008;  83 (2) 81-84
• 11 Malabanan A, Veronikis I E, Holick M F. Redefining vitamin D insufficiency.  Lancet. 1998;  351 (9105) 805-806
• 12 Deluca H F, Cantorna M T. Vitamin D: its role and uses in immunology.  FASEB J. 2001;  15 (14) 2579-2585
• 13 Schleithoff S S, Zittermann A, Tenderich G, Berthold H K, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial.  Am J Clin Nutr. 2006;  83 (4) 754-759
• 14 Cantorna M T, Yu S, Bruce D. The paradoxical effects of vitamin D on type 1 mediated immunity.  Mol Aspects Med. 2008;  29 (6) 369-375
• 15 Adams J S, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity.  Nat Clin Pract Endocrinol Metab. 2008;  4 (2) 80-90
• 16 Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory.  Diabetes Res Clin Pract. 2007;  77 (1) 47-57
• 17 Cohen M L, Douvdevani A, Chaimovitz C, Shany S. Regulation of TNF-alpha by 1alpha,25-dihydroxyvitamin D3 in human macrophages from CAPD patients.  Kidney Int. 2001;  59 (1) 69-75
• 18 Holick M F. Vitamin D deficiency.  N Engl J Med. 2007;  357 (3) 266-281
• 19 Bitetto D, Fabris C, Falleti E et al.. Vitamin D and the risk of acute allograft rejection following human liver transplantation.  Liver Int. 2010;  30 (3) 417-444
• 20 Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages.  J Steroid Biochem Mol Biol. 2007;  103 (3-5) 558-562
• 21 Sun J, Kong J, Duan Y et al.. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor.  Am J Physiol Endocrinol Metab. 2006;  291 (2) E315-E322
• 22 Evans K N, Nguyen L, Chan J et al.. Effects of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on cytokine production by human decidual cells.  Biol Reprod. 2006;  75 (6) 816-822
• 23 Gysemans C A, Cardozo A K, Callewaert H et al.. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice.  Endocrinology. 2005;  146 (4) 1956-1964
• 24 Enioutina E Y, Bareyan D, Daynes R A. TLR-induced local metabolism of vitamin D3 plays an important role in the diversification of adaptive immune responses.  J Immunol. 2009;  182 (7) 4296-4305
• 25 Enioutina E Y, Bareyan D, Daynes R A. Vitamin D3-mediated alterations to myeloid dendritic cell trafficking in vivo expand the scope of their antigen presenting properties.  Vaccine. 2007;  25 (7) 1236-1249
• 26 Ivanov A P, Dragunsky E M, Chumakov K M. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice.  J Infect Dis. 2006;  193 (4) 598-600
• 27 Liu P T, Stenger S, Li H et al.. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.  Science. 2006;  311 (5768) 1770-1773
• 28 Pfeifer M, Begerow B, Minne H W, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals.  Osteoporos Int. 2009;  20 (2) 315-322
• 29 Sato Y, Iwamoto J, Kanoko T, Satoh K. Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial.  Cerebrovasc Dis. 2005;  20 (3) 187-192
• 30 Dhesi J K, Jackson S H, Bearne L M et al.. Vitamin D supplementation improves neuromuscular function in older people who fall.  Age Ageing. 2004;  33 (6) 589-595
• 31 Hoogendijk W J, Lips P, Dik M G, Deeg D J, Beekman A T, Penninx B W. Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults.  Arch Gen Psychiatry. 2008;  65 (5) 508-512
• 32 Miller A H, Maletic V, Raison C L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression.  Biol Psychiatry. 2009;  65 (9) 732-741
• 33 Raison C L, Capuron L, Miller A H. Cytokines sing the blues: inflammation and the pathogenesis of depression.  Trends Immunol. 2006;  27 (1) 24-31
• 34 McCann J C, Ames B N. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?.  FASEB J. 2008;  22 (4) 982-1001
• 35 Wilkins C H, Birge S J, Sheline Y I, Morris J C. Vitamin D deficiency is associated with worse cognitive performance and lower bone density in older African Americans.  J Natl Med Assoc. 2009;  101 (4) 349-354
• 36 Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial.  J Intern Med. 2008;  264 (6) 599-609
• 37 Vieth R, Kimball S, Hu A, Walfish P G. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients.  Nutr J. 2004;  3 8
• 38 Lansdowne A T, Provost S C. Vitamin D3 enhances mood in healthy subjects during winter.  Psychopharmacology (Berl). 1998;  135 (4) 319-323
• 39 Dumville J C, Miles J N, Porthouse J et al.. Can vitamin D supplementation prevent winter-time blues? A randomised trial among older women.  J Nutr Health Aging. 2006;  10 (2) 151-153
• 40 Patel N M, Gutiérrez O M, Andress D L et al.. Vitamin D deficiency and anemia in early chronic kidney disease.  Kidney Int. 2010;  77 (8) 715-720
• 41 Matias P J, Jorge C, Ferreira C et al.. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.  Clin J Am Soc Nephrol. 2010;  5 (5) 905-911
• 42 Kumar V A, Kujubu D A, Sim J J, Rasgon S A, Yang P S. Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients.  J Nephrol. 2011;  24 (1) 98-105
• 43 Kiss Z, Ambrus C, Almasi C et al.. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis.  Nephron Clin Pract. 2011;  117 (4) c373-c378
• 44 Beer T M, Ryan C W, Venner P M ASCENT Investigators et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.  J Clin Oncol. 2007;  25 (6) 669-674
• 45 von Hurst P R, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial.  Br J Nutr. 2010;  103 (4) 549-555
• 46 Bjelakovic G, Gluud L L, Nikolova D et al.. Vitamin D supplementation for prevention of mortality in adults.  Cochrane Database Syst Rev. 2011;  7 (7) CD007470
• 47 Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials.  Arch Intern Med. 2007;  167 (16) 1730-1737
• 48 El-Kamary S S, Jhaveri R, Shardell M D. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population.  Clin Infect Dis. 2011;  53 (2) 150-157
• 49 Elamin M B, Abu Elnour N O, Elamin K B et al.. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis.  J Clin Endocrinol Metab. 2011;  96 (7) 1931-1942
• 50 Pilz S, Iodice S, Zittermann A, Grant W B, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies.  Am J Kidney Dis. 2011;  58 (3) 374-382
• 51 Scragg R. Vitamin D and public health: an overview of recent research on common diseases and mortality in adulthood.  Public Health Nutr. 2011;  14 (9) 1515-1532
• 52 Ginde A A, Scragg R, Schwartz R S, Camargo Jr C A. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults.  J Am Geriatr Soc. 2009;  57 (9) 1595-1603
• 53 Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease.  Dig Dis Sci. 2010;  55 (9) 2624-2628
• 54 Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease.  Clin Gastroenterol Hepatol. 2007;  5 (4) 513-520
• 55 Miroliaee A, Nasiri-Toosi M, Khalilzadeh O, Esteghamati A, Abdollahi A, Mazloumi M. Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study.  Hepatol Int. 2010;  4 (3) 634-640
• 56 Lange C M, Bojunga J, Ramos-Lopez E et al.. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy.  J Hepatol. 2011;  54 (5) 887-893
• 57 Targher G, Bertolini L, Scala L et al.. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease.  Nutr Metab Cardiovasc Dis. 2007;  17 (7) 517-524
• 58 Miroliaee A, Nasiri-Toosi M, Khalilzadeh O, Esteghamati A, Abdollahi A, Mazloumi M. Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study.  Hepatol Int. 2010;  4 (3) 634-640
• 59 George J, Ganesh H K, Acharya S et al.. Bone mineral density and disorders of mineral metabolism in chronic liver disease.  World J Gastroenterol. 2009;  15 (28) 3516-3522
• 60 Masuda S, Okano T, Osawa K et al.. Concentrations of vitamin D-binding protein and vitamin D metabolites in plasma of patients with liver cirrhosis.  J Nutr Sci Vitaminol (Tokyo). 1989;  35 (4) 225-234
• 61 Hepner G W, Roginsky M, Moo H F. Abnormal vitamin D metabolism in patients with cirrhosis.  Am J Dig Dis. 1976;  21 (7) 527-532
• 62 Chakraborti C K. Vitamin D as a promising anticancer agent.  Indian J Pharmacol. 2011;  43 (2) 113-120
• 63 Wu F S, Zheng S S, Wu L J et al.. Calcitriol inhibits the growth of MHCC97 heptocellular cell lines by down-modulating c-met and ERK expressions.  Liver Int. 2007;  27 (5) 700-707
• 64 Pourgholami M H, Akhter J, Lu Y, Morris D L. In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3.  Cancer Lett. 2000;  151 (1) 97-102
• 65 Ghous Z, Akhter J, Pourgholami M H, Morris D L. Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study.  Anticancer Res. 2008;  28 (6A) 3757-3761
• 66 Dalhoff K, Dancey J, Astrup L et al.. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma.  Br J Cancer. 2003;  89 (2) 252-257
• 67 Köstner K, Denzer N, Müller C S, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature.  Anticancer Res. 2009;  29 (9) 3511-3536
• 68 Falleti E, Bitetto D, Fabris C et al.. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis.  World J Gastroenterol. 2010;  16 (24) 3016-3024
• 69 Carey E J, Balan V, Kremers W K, Hay J E. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem.  Liver Transpl. 2003;  9 (11) 1166-1173
• 70 Duarte M P, Farias M L, Coelho H S et al.. Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease.  J Gastroenterol Hepatol. 2001;  16 (9) 1022-1027
• 71 Loria I, Albanese C, Giusto M et al.. Bone disorders in patients with chronic liver disease awaiting liver transplantation.  Transplant Proc. 2010;  42 (4) 1191-1193
• 72 Chen C C, Wang S S, Jeng F S, Lee S D. Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis?.  J Gastroenterol Hepatol. 1996;  11 (5) 417-421
• 73 Goral V, Simsek M, Mete N. Hepatic osteodystrophy and liver cirrhosis.  World J Gastroenterol. 2010;  16 (13) 1639-1643
• 74 Gallego-Rojo F J, Gonzalez-Calvin J L, Muñoz-Torres M et al.. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis.  Hepatology. 1998;  28 (3) 695-699
• 75 Schiefke I, Fach A, Wiedmann M et al.. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection.  World J Gastroenterol. 2005;  11 (12) 1843-1847
• 76 Díez-Ruiz A, García-Saura P L, García-Ruiz P et al.. Bone mineral density, bone turnover markers and cytokines in alcohol-induced cirrhosis.  Alcohol Alcohol. 2010;  45 (5) 427-430
• 77 Guichelaar M M, Kendall R, Malinchoc M, Hay J E. Bone mineral density before and after OLT: long-term follow-up and predictive factors.  Liver Transpl. 2006;  12 (9) 1390-1402
• 78 Guichelaar M M, Schmoll J, Malinchoc M, Hay J E. Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors.  Hepatology. 2007;  46 (4) 1198-1207
• 79 Pack A M, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs.  Cleve Clin J Med. 2004;  71 (Suppl 2) S42-S48
• 80 Solís-Herruzo J A, Castellano G, Fernández I, Muñoz R, Hawkins F. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C.  J Hepatol. 2000;  33 (5) 812-817
• 81 Soumekh A, Bichoupan K, Constable C et al.. Two novel findings about interferon/ribavirin treatment: serum calcium falls and 25-hydroxyvitamin increases. Alexandria, VA: American Association for the Study of Liver Diseases; 2011
• 82 Trombetti A, Giostra E, Mentha G, Negro F, Rizzoli R. Lack of evidence for ribavirin-induced bone loss.  Hepatology. 2002;  36 (1) 255-257
• 83 Nishida N, Komatsu Y, Komeda T, Fukuda Y. Interferon-alpha improves bone resorption and osteopenia in patients with chronic hepatitis C.  Hepatol Res. 2006;  34 (4) 222-227
• 84 Hofmann W P, Kronenberger B, Bojunga J et al.. Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy.  J Viral Hepat. 2008;  15 (11) 790-796
• 85 Framarin L, Avataneo T, Salzedo E et al.. Vertebral osteopenia due to bone marrow hyperplasia during interferon-alpha and ribavirin therapy for chronic hepatitis C.  Dig Liver Dis. 2003;  35 (10) 732-734
• 86 Urganci N, Gulec S G, Arapoglu M, Vural S, Nuhoğ A. The effect of ribavirin on bone density in patients with chronic hepatitis C treated with interferon-ribavirin therapy.  J Pediatr Gastroenterol Nutr. 2005;  41 (5) 650-652
• 87 Weide R, Ehlenz K, Lorenz W et al.. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b.  Ann Hematol. 1996;  72 (1) 41-43
• 88 Moreira R O, Balduíno A, Martins H S et al.. Ribavirin, but not interferon alpha-2b, is associated with impaired osteoblast proliferation and differentiation in vitro.  Calcif Tissue Int. 2004;  75 (2) 160-168
• 89 Lee J, Kim J H, Kim K et al.. Ribavirin enhances osteoclast formation through osteoblasts via up-regulation of TRANCE/RANKL.  Mol Cell Biochem. 2007;  296 (1-2) 17-24
• 90 Takayanagi H, Kim S, Matsuo K et al.. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta.  Nature. 2002;  416 (6882) 744-749
• 91 Choudhary N S, Tomar M, Chawla Y K et al.. Hepatic osteodystrophy is common in patients with noncholestatic liver disease.  Dig Dis Sci. 2011;  56 (11) 3323-3327
• 92 Angulo P, Therneau T M, Jorgensen A et al.. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression.  J Hepatol. 1998;  29 (5) 729-735
• 93 Guañabens N, Parés A, Ros I et al.. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis.  J Hepatol. 2005;  42 (4) 573-577
• 94 Guañabens N, Cerdá D, Monegal A et al.. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis.  Gastroenterology. 2010;  138 (7) 2348-2356
• 95 Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures in chronic liver disease.  Gut. 1990;  31 (1) 82-87
• 96 Monegal A, Navasa M, Guañabens N et al.. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation.  Calcif Tissue Int. 1997;  60 (2) 148-154
• 97 Ninkovic M, Skingle S J, Bearcroft P W, Bishop N, Alexander G J, Compston J E. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation.  Eur J Gastroenterol Hepatol. 2000;  12 (8) 931-935
• 98 Sokhi R P, Anantharaju A, Kondaveeti R, Creech S D, Islam K K, Van Thiel D H. Bone mineral density among cirrhotic patients awaiting liver transplantation.  Liver Transpl. 2004;  10 (5) 648-653
• 99 Brown T T. Bone and Vitamin D. Paper presented at: The 18th Conference on Retroviruses and Opportunistic Infections February 22–March 2, 2011. Boston, MA;
• 100 Childs K E, Fishman S L, Constable C et al.. Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users.  AIDS Res Hum Retroviruses. 2010;  26 (8) 855-859
• 101 Lo Re III V, Guaraldi G, Leonard M B et al.. Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men.  AIDS. 2009;  23 (16) 2191-2198
• 102 El-Maouche D, Mehta S H, Sutcliffe C et al.. Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection.  J Hepatol. 2011;  55 (4) 770-776
• 103 Brown T T, Qaqish R B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.  AIDS. 2006;  20 (17) 2165-2174
• 104 McComsey G A, Tebas P, Shane E et al.. Bone disease in HIV infection: a practical review and recommendations for HIV care providers.  Clin Infect Dis. 2010;  51 (8) 937-946
• 105 Petta S, Cammà C, Scazzone C et al.. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.  Hepatology. 2010;  51 (4) 1158-1167
• 106 Bitetto D, Fattovich G, Fabris C et al.. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.  Hepatology. 2011;  53 (4) 1118-1126
• 107 Terrier B, Carrat F, Geri G et al.. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.  J Hepatol. 2011;  55 (4) 756-761
• 108 Abu-Mouch S M, Fireman Z, Jarchovsky J, Assy N. The beneficial effect of vitamin D with combined peg interferon for chronic HCV infection.  Hepatology. 2009;  50 (4, Suppl) 228A
• 109 Bitetto D, Fabris C, Fornasiere E et al.. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C.  Transpl Int. 2011;  24 (1) 43-50
• 110 Abramovitch S, Dahan-Bachar L, Sharvit E et al.. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats.  Gut. 2011;  60 (12) 1728-1737
• 111 Yano M, Ikeda M, Abe K et al.. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.  Antimicrob Agents Chemother. 2007;  51 (6) 2016-2027
• 112 Yano M, Ikeda M, Abe K et al.. Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase.  Hepatology. 2009;  50 (3) 678-688
• 113 Gutierrez J A, Jones K A, Fitzgerald R L et al.. Vitamin D metabolites inhibit replication of the hepatitis C virus. Abstract presented at: AASLD’s 61st Annual Meeting October 29–November 2, 2010. Boston, MA;
• 114 Gal-Tanamy M, Bachmetov L, Ravid A et al.. Vitamin-D: An innate antiviral agent suppressing Hepatitis C virus in human hepatocytes.  Hepatology. 2011;  54 (5) 1570-1579
• 115 Snellman G, Melhus H, Gedeborg R et al.. Determining vitamin D status: a comparison between commercially available assays.  PLoS ONE. 2010;  5 (7) e11555